Which has better valuation & earnings, BWAY or TMDX?

TransMedics Group has higher revenue and earnings than Brainsway. TransMedics Group is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 10.77 $7.57M $0.35 40.11 TransMedics Group $605.49M 3.98 $190.29M $4.40 15.84

Which has higher valuation and earnings, BWAY or LMAT?

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 10.77 $7.57M $0.35 40.11 LeMaitre Vascular $249.60M 8.39 $57.73M $2.71 33.82

Which has preferable earnings & valuation, BWAY or AXGN?

Brainsway has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 10.77 $7.57M $0.35 40.11 AxoGen $225.21M 9.59 -$15.70M -$0.64 N/A

Is BWAY or AXGN more profitable?

Brainsway has a net margin of 15.68% compared to AxoGen's net margin of -13.21%. Brainsway's return on equity of 12.28% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.68% 12.28% 7.75% AxoGen -13.21% -9.63% -6.26%

Which has preferable valuation & earnings, NVCR or BWAY?

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.85 -$136.23M -$1.53 N/A Brainsway $52.22M 10.77 $7.57M $0.35 40.11

Is NVCR or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Brainsway 15.68% 12.28% 7.75%

Brainsway (BWAY) Competitors

$14.04 -0.52 (-3.57%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$14.39 +0.35 (+2.49%)

As of 06/3/2026 07:37 PM Eastern

Compare

BWAY vs. TMDX, LMAT, AXGN, ESTA, and NVCR

Should you buy Brainsway stock or one of its competitors? MarketBeat compares Brainsway with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainsway include TransMedics Group (TMDX), LeMaitre Vascular (LMAT), AxoGen (AXGN), Establishment Labs (ESTA), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does Brainsway compare to TransMedics Group?

Brainsway (NASDAQ:BWAY) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

TransMedics Group has a net margin of 27.04% compared to Brainsway's net margin of 15.68%. TransMedics Group's return on equity of 22.38% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
TransMedics Group	27.04%	22.38%	8.46%

Brainsway has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

In the previous week, TransMedics Group had 1 more articles in the media than Brainsway. MarketBeat recorded 3 mentions for TransMedics Group and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.02 beat TransMedics Group's score of 0.56 indicating that Brainsway is being referred to more favorably in the media.

Company	Overall Sentiment
Brainsway	Positive
TransMedics Group	Positive

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TransMedics Group has higher revenue and earnings than Brainsway. TransMedics Group is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	10.77	$7.57M	$0.35	40.11
TransMedics Group	$605.49M	3.98	$190.29M	$4.40	15.84

Brainsway presently has a consensus price target of $16.00, suggesting a potential upside of 13.96%. TransMedics Group has a consensus price target of $134.00, suggesting a potential upside of 92.28%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

TransMedics Group beats Brainsway on 11 of the 16 factors compared between the two stocks.

How does Brainsway compare to LeMaitre Vascular?

Brainsway (NASDAQ:BWAY) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, LeMaitre Vascular had 1 more articles in the media than Brainsway. MarketBeat recorded 3 mentions for LeMaitre Vascular and 2 mentions for Brainsway. LeMaitre Vascular's average media sentiment score of 1.04 beat Brainsway's score of 1.02 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainsway	Positive
LeMaitre Vascular	Positive

Brainsway has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	10.77	$7.57M	$0.35	40.11
LeMaitre Vascular	$249.60M	8.39	$57.73M	$2.71	33.82

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LeMaitre Vascular has a net margin of 24.35% compared to Brainsway's net margin of 15.68%. LeMaitre Vascular's return on equity of 15.36% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
LeMaitre Vascular	24.35%	15.36%	9.78%

Brainsway currently has a consensus target price of $16.00, suggesting a potential upside of 13.96%. LeMaitre Vascular has a consensus target price of $112.60, suggesting a potential upside of 22.87%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

LeMaitre Vascular beats Brainsway on 12 of the 16 factors compared between the two stocks.

How does Brainsway compare to AxoGen?

Brainsway (NASDAQ:BWAY) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Brainsway and Brainsway both had 2 articles in the media. AxoGen's average media sentiment score of 1.77 beat Brainsway's score of 1.02 indicating that AxoGen is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainsway	Positive
AxoGen	Very Positive

Brainsway has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

30.1% of Brainsway shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Brainsway has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	10.77	$7.57M	$0.35	40.11
AxoGen	$225.21M	9.59	-$15.70M	-$0.64	N/A

Brainsway presently has a consensus price target of $16.00, suggesting a potential upside of 13.96%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 14.45%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Brainsway has a net margin of 15.68% compared to AxoGen's net margin of -13.21%. Brainsway's return on equity of 12.28% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
AxoGen	-13.21%	-9.63%	-6.26%

Summary

Brainsway beats AxoGen on 10 of the 15 factors compared between the two stocks.

How does Brainsway compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Establishment Labs has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Brainsway has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	10.10	-$51.06M	-$1.49	N/A
Brainsway	$52.22M	10.77	$7.57M	$0.35	40.11

Brainsway has a net margin of 15.68% compared to Establishment Labs' net margin of -19.05%. Brainsway's return on equity of 12.28% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Brainsway	15.68%	12.28%	7.75%

In the previous week, Establishment Labs and Establishment Labs both had 2 articles in the media. Establishment Labs' average media sentiment score of 1.49 beat Brainsway's score of 1.02 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Establishment Labs	Positive
Brainsway	Positive

Establishment Labs presently has a consensus target price of $87.14, suggesting a potential upside of 20.35%. Brainsway has a consensus target price of $16.00, suggesting a potential upside of 13.96%. Given Establishment Labs' higher possible upside, analysts clearly believe Establishment Labs is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Brainsway beats Establishment Labs on 10 of the 15 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

NovoCure currently has a consensus price target of $27.29, suggesting a potential upside of 68.95%. Brainsway has a consensus price target of $16.00, suggesting a potential upside of 13.96%. Given NovoCure's higher probable upside, equities analysts plainly believe NovoCure is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Brainsway	15.68%	12.28%	7.75%

NovoCure has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

In the previous week, NovoCure had 6 more articles in the media than Brainsway. MarketBeat recorded 8 mentions for NovoCure and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.02 beat NovoCure's score of 0.93 indicating that Brainsway is being referred to more favorably in the news media.

Company	Overall Sentiment
NovoCure	Positive
Brainsway	Positive

84.6% of NovoCure shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.85	-$136.23M	-$1.53	N/A
Brainsway	$52.22M	10.77	$7.57M	$0.35	40.11

Summary

Brainsway beats NovoCure on 11 of the 16 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$583.13M	$8.16B	$6.47B	$12.54B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	40.12	15.39	22.39	24.18
Price / Sales	10.77	7.06	520.79	112.26
Price / Cash	62.19	17.10	41.34	57.13
Price / Book	7.51	3.53	9.84	6.72
Net Income	$7.57M	$224.05M	$3.57B	$337.19M
7 Day Performance	-11.59%	-3.00%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	168.45%	-0.26%	26.49%	33.10%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	3.7365 of 5 stars	$14.04 -3.6%	$16.00 +14.0%	+175.6%	$583.13M	$52.22M	40.12	120	Positive News Gap Down
TMDX TransMedics Group	4.6024 of 5 stars	$70.11 +1.7%	$135.00 +92.6%	-45.9%	$2.42B	$605.49M	15.93	210
LMAT LeMaitre Vascular	4.8624 of 5 stars	$98.31 +0.6%	$112.60 +14.5%	+10.6%	$2.25B	$249.60M	36.28	490	Positive News Analyst Forecast
AXGN AxoGen	2.9602 of 5 stars	$41.15 +0.6%	$46.50 +13.0%	+257.7%	$2.19B	$225.21M	N/A	450	Positive News
ESTA Establishment Labs	2.8926 of 5 stars	$74.03 +2.5%	$87.14 +17.7%	+97.3%	$2.18B	$211.08M	N/A	1,004	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. TMDX, LMAT, AXGN, ESTA, and NVCR

How does Brainsway compare to TransMedics Group?

Summary

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to AxoGen?

Summary

How does Brainsway compare to Establishment Labs?

Summary

How does Brainsway compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. TMDX, LMAT, AXGN, ESTA, and NVCR

How does Brainsway compare to TransMedics Group?

Is BWAY or TMDX more profitable?

Which has more risk & volatility, BWAY or TMDX?

Does the media refer more to BWAY or TMDX?

Do insiders & institutionals hold more shares of BWAY or TMDX?

Which has better valuation & earnings, BWAY or TMDX?

Do analysts prefer BWAY or TMDX?

Summary

How does Brainsway compare to LeMaitre Vascular?

Does the media refer more to BWAY or LMAT?

Which has more risk and volatility, BWAY or LMAT?

Which has higher valuation and earnings, BWAY or LMAT?

Do insiders and institutionals hold more shares of BWAY or LMAT?

Is BWAY or LMAT more profitable?

Do analysts prefer BWAY or LMAT?

Summary

How does Brainsway compare to AxoGen?

Does the media prefer BWAY or AXGN?

Which has more volatility and risk, BWAY or AXGN?

Do insiders & institutionals believe in BWAY or AXGN?

Which has preferable earnings & valuation, BWAY or AXGN?

Do analysts prefer BWAY or AXGN?

Is BWAY or AXGN more profitable?

Summary

How does Brainsway compare to Establishment Labs?

Do insiders and institutionals hold more shares of ESTA or BWAY?

Which has more volatility & risk, ESTA or BWAY?

Which has higher earnings & valuation, ESTA or BWAY?

Is ESTA or BWAY more profitable?

Does the media favor ESTA or BWAY?

Do analysts rate ESTA or BWAY?

Summary

How does Brainsway compare to NovoCure?

Do analysts rate NVCR or BWAY?

Is NVCR or BWAY more profitable?

Which has more risk and volatility, NVCR or BWAY?

Does the media refer more to NVCR or BWAY?

Do institutionals & insiders hold more shares of NVCR or BWAY?

Which has preferable valuation & earnings, NVCR or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools